Pulmonary involvement in long-term mixed connective tissue disease: Functional trends and imaging findings after 10 years

Clinical and Experimental Rheumatology

Volumn 33, Issue 2, 2015, Pages 234-240

  Kawano Dourado, Leticia ^a   Baldi, Bruno G ^a   Kay, Fernando U ^a   Dias, Olivia M ^a   Gripp, Thais E H ^b   Gomes, Paula S ^a   Fuller, Ricardo ^a   Caleiro, Maria T C ^a   Kairalla, Ronaldo A ^a   Carvalho, Carlos R R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

Author keywords

High resolution computed tomography; Interstitial lung disease; Mixed connective tissue disease; Pulmonary function test

Indexed keywords

CARBON MONOXIDE;

ADULT; ARTICLE; BRONCHIECTASIS; CAUSE OF DEATH; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HONEYCOMBING; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MALE; MIXED CONNECTIVE TISSUE DISEASE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SCORING SYSTEM; SPIROMETRY; TREND STUDY; COMPLICATION; DISEASE COURSE; LUNG; LUNG DISEASES, INTERSTITIAL; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; TIME; VITAL CAPACITY;

ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; PULMONARY DIFFUSING CAPACITY; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84929939081     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. KASUKAWA R: Mixed connective tissue disease. Intern Med. 1999; 38: 386-93.
2. SHARP GC, IRVIN WS, TAN EM, GOULD RG, HOLMAN HR: Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52: 148-59.
3. SHARP GC, HOFFMAN RW: Clinical, immunologic, and immunogenetic evidence that mixed connective tissue disease is a distinct entity: comment on the article by Smolen and Steiner. Arthritis Rheum 1999; 42: 190-1; reply 3-6.
4. GUNNARSSON R, AALØKKEN TM, MOLBERG Ø et al.: Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis 2012; 71: 1966-72.
5. BURDT MA, HOFFMAN RW, DEUTSCHER SL, WANG GS, JOHNSON JC, SHARP GC: Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42: 899-909.
6. BODOLAY E, SZEKANECZ Z, DéVéNYI K et al.: Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford) 2005; 44: 656-61.
7. IZUMIYAMA T, HIDA W, ICHINOSE M et al.: Small airway involvement in mixed connective tissue disease. Tohoku J Exp Med 1993; 170: 273-83.
8. SULLIVAN WD, HURST DJ, HARMON CE et al.: A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984; 63: 92-107.
9. FAGUNDES MN, CALEIRO MT, NAVARRO-RODRIGUEZ T et al.: Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respir Med 2009; 103: 854-60.
10. MACINTYRE N, CRAPO RO, VIEGI G et al.: Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720-35.
11. MILLER MR, HANKINSON J, BRUSASCO V et al.: Standardisation of spirometry. Eur Respir J 2005; 26: 319-38.
12. WANGER J, CLAUSEN JL, COATES A et al.: Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511-22.
13. PEREIRA CA, SATO T, RODRIGUES SC: New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol 2007; 33: 397-406.
14. NEDER JA, ANDREONI S, CASTELO-FILHO A, Nery LE. Reference values for lung function tests. I. Static volumes. Braz J Med Biol Res 1999; 32: 703-17.
15. NEDER JA, ANDREONI S, PERES C, NERY LE: Reference values for lung function tests. III. Carbon monoxide diffusing capacity (transfer factor). Braz J Med Biol Res 1999; 32: 729-37.
16. HANSELL DM, BANKIER AA, MacMAHON H, MCLOUD TC, MüLLER NL, REMY J: Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246: 697-722.
17. BHALLA M, SILVER RM, SHEPARD JA, McLOUD TC: Chest CT in patients with scleroderma: prevalence of asymptomatic esophageal dilatation and mediastinal lymphadenopathy. Am J Roentgenol 1993; 161: 269-72.
18. MARTEN K, DICKEN V, KNEITZ C et al.: Interstitial lung disease associated with collagen vascular disorders: disease quantification using a computer-aided diagnosis tool. Eur Radiol 2009; 19: 324-32.
19. KHANNA D, TSENG CH, FARMANI N et al.: Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63: 3078-85.
20. KOZUKA T, JOHKOH T, HONDA O et al.: Pulmonary involvement in mixed connective tissue disease: high-resolution CT findings in 41 patients. J Thorac Imaging 2001; 16: 94-8.
21. SAITO Y, TERADA M, TAKADA T et al.: Pulmonary involvement in mixed connective tissue disease: comparison with other collagen vascular diseases using high resolution CT. J Comput Assist Tomogr 2002; 26: 349-57.
22. FERRI C, VALENTINI G, COZZI F et al.: Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 139-53.
23. BJORAKER JA, RYU JH, EDWIN MK et al.: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203.
24. KING TE, BEHR J, BROWN KK et al.: BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
25. RAGHU G, BROWN KK, BRADFORD WZ et al.: A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-33.
26. PLASTIRAS SC, KARADIMITRAKIS SP, ZIAKAS PD, VLACHOYIANNOPOULOS PG, MOUTSOPOULOS HM, TZELEPIS GE: Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55: 598-602.
27. WELLS AU, HANSELL DM, RUBENS MB et al.: Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40: 1229-36.
28. BOUROS D, WELLS AU, NICHOLSON AG et al.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-6.
29. LATSI PI, du BOIS RM, NICHOLSON AG et al.: Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-7.
30. SCHMIDT SL, TAYOB N, HAN MK et al.: Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 2014; 145: 579-85.
31. MARTINEZ FJ, FLAHERTY K: Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 315-21.
32. WELLS AU, KING AD, RUBENS MB, CRAMER D, du BOIS RM, HANSELL DM: Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997; 155: 1367-75.
33. BALDI BG, PEREIRA CA, RUBIN AS et al.: Highlights of the Brazilian Thoracic Association guidelines for interstitial lung diseases. J Bras Pneumol 2012; 38: 282-91.
34. SZODORAY P, HAJAS A, KARDOS L et al.: Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus 2012; 21: 1412-22.
35. GOH NS, DESAI SR, VEERARAGHAVAN S et al.: Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.